MedTrace Logo

Late Acquired Malaposition and Different Polymers

NCT02018991 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2013-12-30

No results posted yet for this study

Summary

The polymers releasing the drug of first-generation drug-eluting stents (DES) may induce allergic reactions and inflammation, resulting in late-acquired stent malaposition (LASM) with uncoverage of struts, and risk of stent thrombosis. The incidence and predictors of LASM in DES with newer-generation polymers designed to improve biocompatibility are unknown.

Conditions

  • Late Acquired Stent Malaposition

Interventions

PROCEDURE

Everolimus-Eluting Stent (EES)

Patients treated with EES

PROCEDURE

Zotarolimus-Eluting-Stent (ZES)

Patients treated with ZES

PROCEDURE

Biolimus-Eluting-Stent (BES)

Patients treated with BES

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Thomas Neunteufl, Prof. Dr. · PI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02018991 on ClinicalTrials.gov